early detection of gastric cancer among asymptomatic middle-aged Japanese. Nearly half a century has passed since a mass photofluorography screening program for gastric cancer were initiated, which has no doubt contributed to lessen gastric cancer deaths in Japan. A population-based, case–control study showed that screening for gastric cancer at 5-year intervals might reduce mortality by 60%.[16] However, recent demands are in the direction of cure without gastrectomy; that is, endoscopic resection, or less radical treatment, if possible, for obtaining a better quality of life. Miki *et al.* reported the incidence of gastric cancer to be 0.05% by photofluorography and 0.18% by PG measurement in populations who underwent photofluorography and PG measurement simultaneously, and that 90% of gastric cancers detected by the PG measurement were in the early stage.[10] Another advantage of PG measurement may be no radiation exposure, no adverse events, much less man-power or reduced costs[17] etc. When considering these factors, serum PG measurement is considered to be quite reasonable for mass screening of gastric cancer.

In spite of these advantages over photofluorography, there has been a major criticism to prevent widespread use of PG measurement for mass screening of gastric cancer, pointing to a lack of data for reduced gastric mortality using this method. Finally, a recent study revealed the reduction in gastric cancer mortality by screening based on PG measurement, which showed that odds ratios for death from gastric cancer among control subjects screened within 1 and 2 years before the individuals were diagnosed versus those who not screened were 0.238 and 0.375, respectively.[18] Thus, we are convinced that PG measurement for mass screening of gastric cancer seems superior to photofluorography, although further studies are needed to obtain final conclusions.

We recognize that a limitation of this study may be that it is impossible to elucidate the accuracy of this screening method from the cross-sectional study setting. The major reason why we used detection rate as an outcome measurement in this study is the difficulty in following most participating individuals due to their being transferred to another workplace branch within a few years. In spite of the drawback, we believe that this study was meaningful for the following reasons. First, all individuals of the mass-screening were enrolled for PG measurement by serum samples obtained at an annual medical check-up and 65% of individuals intended for gastroendoscopy did undergo gastroendoscopy, which is much higher than the proportions who underwent photofluorography; second, gastric cancer was detected in 0.1% of all participants and in 0.9% of those who underwent gastroendoscopy, which is not less than the proportions obtained with photofluorography; third, early-stage cancers accounted for 80% of all detected cancers, which is also much higher than the proportions obtained with photofluorography; fourth, 39% of all the detected cancers were intestinal-type intramucosal cancers, which are considered to be potentially curable by endoscopic resection.

In summary, 15 years experience of serum PG measurement for mass screening of gastric cancer revealed high recruitment for gastroendoscopy in intended individuals, a favorable detection rate of gastric cancer in asymptomatic individuals and, in particular, an extremely high proportion of early-stage gastric cancer in all the detected cancers. Further studies are needed to evaluate our new mass-screening method, namely, the serum pepsinogen test method, as one of the world standards for gastric cancer screening within Japan and worldwide.

REFERENCES

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. *CA Cancer J. Clin.* 2005; **55**: 74–108.
2. Foundation for Promotion of Cancer Research. *Cancer Statistics in Japan – 2005*. Tokyo: Foundation for Promotion of Cancer Research, 2005.
3. Leung WK, Wu MS, Kakugawa Y *et al.* Screening of gastric cancer in Asia: Current evidence and practice. *Lancet Oncol.* 2008; **9**: 279–87.
4. Parthasarathy G, Maroju NK, Kate V, Ananthakrishnan N, Sridhar MG. Serum pepsinogen I and II levels in various gastric disorders with special reference to their use as a screening test for carcinoma stomach. *Trop. Gastroenterol.* 2007; **28**: 166–70.
5. Cao Q, Ran ZH, Xiao SD. Screening of atrophic gastritis and gastric cancer by serum pepsinogen, gastrin-17 and Helicobacter pylori immunoglobulin G antibodies. *J. Dig. Dis.* 2007; **8**: 15–22.
6. Miki K, Urita Y. Using serum pepsinogens wisely in a clinical practice. *J. Dig. Dis.* 2007; **8**: 8–14.
7. Sasazuki S, Inoue M, Iwasaki M *et al.* Effect of Helicobacter pylori infection combined with CagA and pepsinogen status on gastric cancer development among Japanese men and women: A nested case-control study. *Cancer Epidemiol. Biomarkers Prev.* 2006; **15**: 1341–7.
8. Oishi Y, Kiyohara Y, Kubo M *et al.* The serum pepsinogen test as a predictor of gastric cancer: The Hisayama study. *Am. J. Epidemiol.* 2006; **163**: 629–37.
9. Miki K, Ichinose M, Kawamura N *et al.* The significance of low serum pepsinogen levels to detect stomach cancer associated with extensive chronic gastritis in Japanese subjects. *Jpn. J. Cancer Res.* 1989; **80**: 111–14.
10. Miki K, Morita M, Sasajima M *et al.* Usefulness of gastric cancer screening using the serum pepsinogen test method. *Am. J. Gastroenterol.* 2003; **98**: 735–9.
11. Miki K. Gastric cancer screening using the serum pepsinogen test method. *Gastric Cancer* 2006; **9**: 245–53.
12. Dinis-Ribeiro M, Yamaki G, Miki K, Costa-Pereira A, Matsukawa M, Kurihara M. Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. *J. Med. Screen* 2004; **11**: 141–7.
13. Fujishiro M, Yahagi N, Kakushima N *et al. Early detection of asymptomatic gastric cancers using serum pepsinogen levels to indicate endoscopic submucosal dissection for better quality of life*. In: Kitajima M and Otani Y (eds). *Proceedings of 6th International Gastric Cancer Congress*. Bologna: Medimond S.r.l., 2005; 145–50.
14. Miki K, Ichinose M, Kakei N *et al.* The clinical application of the serum pepsinogen I and II levels as mass screening method for gastric cancer. In: Takahashi K (ed.). *Aspartic Proteinases: Structure, Function, Biology and Biomedical Implications*. New York: Plenum Press, 1995; 139–43.
15. Fujishiro M. Endoscopic resection for early gastric cancer. In: Kaminishi M, Takubo K, Mafune K (eds). *The Diversity of Gastric Carcinoma; Pathogenesis, Diagnosis, and Therapy*. Tokyo: Springer-Verlag Tokyo, 2005; 243–52.
16. Fukao A, Tsubono Y, Tsuji I, Hisamichi S, Sugahara N, Takano A. The evaluation of screening for gastric cancer in

© 2009 The Authors
© 2009 Japan Gastroenterological Endoscopy Society

Miyagi Prefecture, Japan: A population-based case-control study. *Int. J. Cancer* 1995; **60**: 45–8.
17. Ohata H, Oka M, Yanaoka K *et al.* Gastric cancer screening of a high-risk population in Japan using serum pepsinogen and barium digital radiography. *Cancer Sci.* 2005; **96**: 713–20.
18. Yoshihara M, Hiyama T, Yoshida S *et al.* Reduction in gastric cancer mortality by screening based on serum pepsinogen concentration: A case-control study. *Scand J. Gastroenterol.* 2007; **42**: 760–4.

© 2009 The Authors
© 2009 Japan Gastroenterological Endoscopy Society

Digestive Endoscopy (2009) **21**, 134–135 doi:10.1111/j.1443-1661.2009.00845.x

LETTER TO THE EDITOR

Cautious comparison between East and West is necessary in terms of the serum pepsinogen test

Dear Editor,

It is well known that *Helicobacter pylori* (*H. pylori*) infection plays a major role in the carcinogenesis of gastric cancers. The hypothesis established by Correa is widely accepted and various types of evidence to support it have been accumulated.[1] According to the hypothesis, chronic atrophic gastritis (CAG) induced by *H. pylori* infection is considered to be the first step of sequential mucosal changes leading to the gastric cancer.

Our previous study showed that progression of CAG was well correlated with a stepwise reduction in serum pepsinogen (PG) levels, which consisted of two types: PGI and PGII. The PGI level decreases with loss of fundic gland mucosa, whereas PGII remains constant.[2] Therefore, a low PGI level and a low PGI/II ratio are good indicators of CAG and a PGI level ≤70 ng/mL and a PGI/PGII ratio ≤3 are common cut-offs used for the identification of patients with CAG.[3] In a pooled analysis of Japanese studies that assessed approximately 300 000 people using the criteria, the sensitivity of serum PG testing for gastric cancer screening was 77% and the specificity was 73%.[4] This type of meta-analysis is possible in Japan, because both a correlation coefficient and an inclination among all the available kits for the measurement of serum PG levels from Japanese companies show values nearly equal to 1, which gives almost the same results in absolute values of PG levels.[5]

Recently, a convenient set of kits for four biomarkers, PGI, PGII, gastrin-17, and *H. pylori* antibody, has been released as the GastroPanel examination (Biohit Plc., Helsinki, Finland) to evaluate dyspepsia, *H. pylori* infection, CAG and related risks such as gastric cancer.[6] Although the concept is reasonable and should be forwarded, one of our major concerns is the use of different calibrations to obtain the absolute levels of PG compared with Japanese kits. Figure 1 shows correlations of the PG levels between a representative Japanese kit (LZ-test EIKEN; Eiken Chemical Co., Tokyo, Japan) and the GastroPanel examination. For 304 blood samples obtained from asymptomatic individuals living in Tokyo, the correlation coefficients of PGI, PGII and the PGI/II ratio were 0.981, 0.976 and 0.920, respectively. These values showed very strong correlations between the two kits, but inclinations of PGI, PGII and the PGI/II ratio were 1.3804, 0.8321 and 2.1997, respectively. These findings imply that PGI, PGII and the PGI/II ratio obtained by the GastroPanel examination is approximately 40% higher, 20% lower, and twofold higher than those obtained by the Japanese kits, respectively. Thus, cautious comparison between East and West is necessary in terms of interpreting the results of measurements of PG levels obtained using kits with different calibration. This may cause some confusion in daily practice when evidence-based medicine is promoted.

KAZUMASA MIKI[1] AND MITSUHIRO FUJISHIRO[2]
[1]*Japan Research Foundation of Prediction, Diagnosis and Therapy for Gastric Cancer (JRF PDT GC)*



Fig. 1. Correlations of the pepsinogen test between LZ-test EIKEN and GastroPanel. (a) Correlation of the pepsinogen I level, (b) correlation of the pepsinogen II level, (c) correlation of the pepsinogen I/II ratio.

© 2009 The Authors
© 2009 Japan Gastroenterological Endoscopy Society

and
[2]Department of Gastroenterology/Internal Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

REFERENCES

1. Correa P. Human gastric carcinogenesis: A multistep and multifactorial process – First American Cancer Society Award Lecture on cancer epidemiology and prevention. *Cancer Res.* 1992; **52**: 6735–40.
2. Miki K, Ichinose M, Shimizu A *et al.* Serum pepsinogens as a screening test of extensive chronic gastritis. *Gastroenterol. Jpn.* 1987; **22**: 133–41.
3. Miki K, Ichinose M, Kakei N *et al.* The clinical application of the serum pepsinogen I and II levels as mass screening method for gastric cancer. In: Takahashi K (ed.). *Aspartic Proteinases: Structure, Function, Biology and Biomedical Implications*. New York: Plenum Press, 1995; 139–43.
4. Dinis-Ribeiro M, Yamaki G, Miki K, Costa-Pereira A, Matsukawa M, Kurihara M. Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. *J. Med. Screen.* 2004; **11**: 141–7.
5. Miki K. Gastric cancer screening using the serum pepsinogen test method. *Gastric Cancer* 2006; **9**: 245–3.
6. Biohit Corporation. *GastroPanel*. [Cited 22 January 2009.] Available from URL: http://www.biohit.com/gastropanel.

© 2009 The Authors
© 2009 Japan Gastroenterological Endoscopy Society

EXPERIMENTAL CELL RESEARCH 315 (2009) 1779–1789

available at www.sciencedirect.com

ScienceDirect

www.elsevier.com/locate/yexcr



Research Article

Cdx2 and the Brm-type SWI/SNF complex cooperatively regulate *villin* expression in gastrointestinal cells☆

Nobutake Yamamichi[a,b], *Ken-ichi Inada*[c], *Chihiro Furukawa*[a], *Kouhei Sakurai*[a], *Toshio Tando*[a], *Aya Ishizaka*[a], *Takeshi Haraguchi*[a], *Taketoshi Mizutani*[a], *Mitsuhiro Fujishiro*[b], *Ryoichi Shimomura*[c], *Masashi Oka*[d], *Masao Ichinose*[d], *Yutaka Tsutsumi*[c], *Masao Omata*[b], *Hideo Iba*[a,*]

[a]*Division of Host-Parasite Interaction, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, 4-6-1, Shirokanedai Minato-ku, Tokyo 108-8639, Japan*
[b]*Department of Gastroenterology, Faculty of Medicine, University of Tokyo, Tokyo, Japan*
[c]*1st Department of Pathology, Fujita Health University School of Medicine, Aichi, Japan*
[d]*Second Department of Internal Medicine, Wakayama Medical College, Wakayama, Japan*

ARTICLE INFORMATION

Article Chronology:
Received 13 November 2008
Revised version received
14 January 2009
Accepted 14 January 2009
Available online 22 January 2009

Keywords:
Villin
Cdx2
Brm
SWI/SNF complex
Gastric cancer

ABSTRACT

In our recent study showing a correlation between Brm-deficiency and undifferentiated status of gastric cancer, we found that the Brm-type SWI/SNF complex is required for *villin* expression. To elucidate intestinal *villin* regulation more precisely, we here analyzed structure and function of the promoter of human *villin*. About 1.1 kb upstream of the determined major transcription start site, we identified a highly conserved region (HCR-Cdx) among mammals, which contains two binding sites for Cdx. Expression analyses of 30 human gastrointestinal cell lines suggested that *villin* is regulated by Cdx2. Introduction of *Cdx* family genes into colorectal SW480 cells revealed that *villin* is strongly induced strongly by Cdx2, moderately by Cdx1, and marginally by Cdx4. Knockdown of Cdx2 in SW480 cells caused a clear downregulation of *villin*, and reporter assays showed that HCR-Cdx is crucial for Cdx2-dependent and Brm-dependent *villin* expression. Immunohistochemical analyses of gastric intestinal metaplasia and cancer revealed that villin and Cdx2 expression are tightly coupled. GST pull-down assays demonstrated a direct interaction between Cdx2 and several SWI/SNF subunits. Chromatin immunoprecipitation analyses showed the recruitment of Cdx2 and Brm around HCR-Cdx. From these results, we concluded that Cdx2 regulates intestinal *villin* expression through recruiting Brm-type SWI/SNF complex to the *villin* promoter.

© 2009 Elsevier Inc. All rights reserved.

☆ Grant support/financial disclosures: This work was supported in part by a Grant-in-Aid for Scientific Research on Priority Areas from the Ministry of Education, Cultures, Sports, Science, and Technology of Japan; and was also supported in part by Strategic cooperation to control emerging and reemerging infections funded by the Special Coordination Funds for Promoting Science and Technology of Ministry of Education, Culture, Sports, Science and Technology (MEXT). None of the authors have any conflicts of interest associated with this study. We disclosed potential conflicts to all the study participants.

* *Corresponding author.* Fax: +81 3 5449 5449.
E-mail address: iba@ims.u-tokyo.ac.jp (H. Iba).

0014-4827/$ – see front matter © 2009 Elsevier Inc. All rights reserved.
doi:10.1016/j.yexcr.2009.01.006

Introduction

Villin is a calcium-regulated actin-binding protein that modulates the structure and assembly of actin filaments [1–3]. In normal adult tissues, the expression of villin is observed in epithelial cells of the small and large intestinal mucosa, kidney proximal tubules, intrahepatic bile ducts, pancreatic ducts, gall bladder epithelium, and so on [1,4]. It has also been reported that villin is expressed in the proliferative stem cells of the intestinal crypts [5]. In terms of its pathophysiology, villin expression is induced in the intestinal metaplasia observed in Barrett's esophagus and in chronic atrophic gastritis [1,6]. In addition, villin is also frequently found to be expressed in human adenocarcinomas, especially those of intestinal origin [1,7]. Based upon the evidence produce to date, villin is considered as one of the most important intestinal differentiation markers.

In our previous study, we examined the expression of Brm and BRG1 in human gastric cancer cell lines and primary stomach cancers, and found that only Brm is frequently deficient in gastric malignancies [8]. Brm and BRG1 are alternative catalytic subunits of the SWI/SNF chromatin remodeling complex, which involves expression of a vast majority of genes such as *CD44* [9,10], *MMP-1* [10], *E-cadherin* [9], etc. We also demonstrated that the Brm-type SWI/SNF complex plays crucial roles in regulating *villin* expression in these gastric cancer cells; *villin* transcripts are undetectable in most of the Brm-deficient cell lines that were tested, and we observed a clear induction of *villin* in these cells upon the exogenous introduction of Brm but not BRG1 [8]. We have also observed a clear correlation between the Brm-deficiency status and the histologic appearance of gastric malignancy. Of note, in the major gastric cancer types (well or moderately differentiated tubular adenocarcinoma and poorly differentiated adenocarcinoma), frequent loss of Brm expression was found to positively correlate with the undifferentiated status.

In our present study, we analyzed the regulation of intestinal *villin* expression in a more precise fashion using 32 human cancer cell lines and clinical tissues from 39 gastric cancer patients. We anticipate that such accurate analyses of *villin* expression will facilitate the future elucidation of not only the regulatory pathways in intestinal differentiation, but also the roles of Brm in determining the histologic features of gastric cancer.

Materials and methods

Cell culture

Six gastric cancer cell lines (KE-39, KE-97, HuG1-N, HuG1-PI, ECC-10, and ECC-12) were maintained in RPMI1640 with 10% fetal calf serum (Gibco/Invitrogen Corp., Carlsbad, CA) at 37 °C. Other 14 gastric cancer cell lines, 10 colorectal cancer cell lines, and two non-gastrointestinal cancer cell lines (HeLa-S3 and MDA-MB435) were grown in DMEM with 10% fetal calf serum (Gibco/Invitrogen) at 37 °C.

RT-PCR

Total cellular RNAs were prepared using the Isogen RNA isolation reagent (Wako Pure Chemical Industries, Osaka, Japan). Semi-quantitative RT-PCR was performed via a Superscript One-Step reaction using the Platinum Taq (Invitrogen). The primers used to map the TSS of *villin* are shown in the Supplementary materials and methods. The primer pairs and RT-PCR procedures employed to detect the expression levels of the *villin*, *GAPDH*, *Cdx2*, *Cdx1*, *Cdx4*, and *LI-cadherin* are also shown.

Western blotting

Immunoblotting was performed as described previously [11], using the antibodies anti-Cdx2 mouse monoclonal (CDX2-88, Biogenex, San Ramon, CA, 1:200), anti-Brm rabbit polyclonal (Transgenic Inc., Kumamoto, Japan, 1:300), and anti-β-actin mouse monoclonal (Ab-5, BD Transduction, Lexington, KY, 1:2000). Specific bands were detected using the ECL kit (Amersham, Piscataway, NJ).

5′-Rapid amplification of cDNA ends (5′-RACE)

Total RNA was extracted from NUGC-4 cells and subjected to 5′-RACE as described previously [8].

Primer extension and sequencing

To determine the TSSs of the *villin* gene, primer extension analyses were undertaken in parallel with sequencing of the same region by dideoxy chain-termination reaction. Aliquots equaling 9 μg of total RNA from NUGC-4 and AZ521 cells were reverse transcribed with SuperScript III (Invitrogen) and with a 5′-^{32}P-labeled 5′-tggtgat-gttgagagagccttt-3′ primer (designed using the sequence just downstream of the ATG translation start site of *villin*). To obtain DNA templates for use in the dideoxy chain-termination reaction, NUGC-4 genomic DNA was amplified with the primers 5′-gcagaacagagttcaaaggcact-3′ and 5′-ctgtcttggggaggcagctgc-3′. The resulting PCR products were then fused to the 5′-RACE products inserted in the pCR2.1 TA cloning vector (Invitrogen). The PCR2.1 construct containing an upstream sequence (1183 bp), exon 1, exon 2, exon 3 and a portion of exon 4 of the *villin* gene was thus made. Single-stranded DNAs were synthesized from the same 5′-^{32}P-labeled primer described above using ΔTth DNA polymerase (TOYOBO Co., Tokyo, Japan) in the presence of dideoxynucleotides. Primer extension products and DNA ladders were separated on 10% polyacrylamide gels containing 7 M urea. This gel was then dried and visualized with an image analyzer (FLA5100, Fujifilm, Tokyo, Japan).

Immunohistochemistry

Deparaffinization, endogenous peroxidase inactivation, and antigen retrieval of FFPE clinical tissues were performed as described previously [8]. Immunostaining and signal amplification with anti-villin (Clone-12, BD Transduction) or anti-Cdx2 (CDX2-88, Biogenex) antibodies were also undertaken as described previously [12]. The immunostained sections were evaluated independently by two pathologists in conjunction with the hematoxylin and eosin stained sections from the same lesions.

Retrovirus vectors

Vesicular stomatitis virus G protein (VSV-G)-pseudotyped, MuLV-based retrovirus vectors were prepared using the PLAT prepackaging cell line [13]. To generate vectors expressing Cdx, cDNA inserts for

Cdx2, *Cdx1*, and *Cdx4* was cloned into the EcoRI site of the pMXs-IRES-Puro retroviral vector (Cell Biolabs Inc., San Diego, CA). How to obtain the full length cDNA for *Cdx2*, *Cdx1*, and *Cdx4* was described in Supplementary materials and methods. Viral constructs encoding shCdx2 targeting 5′-gccaaaggcagctaagataga-3′ and 5′-gcccgaacagggacttgttta-3′ sequences of human *Cdx2* ("shCdx2-1" and "shCdx2-2" respectively), shBrm targeting the 5′-gaatgtggtgttggtgctttc-3′ sequence of human *Brm*, shBRG1 targeting the 5′-gtagctccgaggtctgatagt-3′ sequence of human *BRG1*, shIni1 targeting the 5′-gacatgtcagagaaggagaac-3′ sequence of human *Ini1*, and shGFP targeting *GFP* were prepared as described previously [11].

Luciferase reporter assay

SW480 cells (3×10^4) were seeded in 96-well (0.32 cm^2) plates, and transfected with 6.5 ng of Renilla luciferase control vector pGL4.74 (Promega, Madison, WI), and either 200 ng of Firefly luciferase experimental vector pGL4.12 (Promega), pGL4.12-



Fig. 1 – (A) Sequences around the transcription initiation sites of the human *villin* gene. Exons 1 and 2 are highlighted by the gray boxes. Three rectangular arrows indicate the 5′-ends of the *villin* transcripts identified using 5′-RACE, and the numbers of clones obtained in this analysis are denoted in parentheses. The ATG translation start codon of the *villin* gene in the exon 2 is also indicated, as is the presumed TATA box in the gene promoter (underlined). (B) Determination of the TSS of the human *villin* gene by primer extension analysis. Villin-expressing NUGC-4 and villin-deficient AZ521 cells were used, and two clear bands (indicated by arrows) were specifically detected in only the NUGC-4 cells. These bands correspond to the TSSs determined by 5′-RACE in (A). (C) RT-PCR analysis of human *villin* using a reverse primer located in the exon 6 (R1) and four forward primers located in the upstream region of exon 2 (F-1/F-2/F-3/F-4). The sequence locations corresponding to each primer are shown in the upper schema, in which the three TSSs determined by primer extension and 5′-RACE are also shown.

villinBX, pGL4.12-villinI, pGL4.12-villinII, or pGL4.12-villinIII. Construction of each vector plasmid was described in the Supplementary materials and methods. All transfections were performed with Lipofectamine2000 Reagent and Lipofectamine PLUS (Invitrogen). Luciferase activities were measured at 48 h post-transfection using the Dual luciferase reporter assay system (Promega).

Chromatin immunoprecipitation (ChIP) assay

ChIP analyses were performed using a ChIP assay kit (Upstate Biotechnology Inc., Lake Placid, NY) according to the manufacturer's instructions. For crosslinking, SW480 cells or HT-29 cells (5×10^6) were incubated at 37 °C for 15 min in PBS containing 1% formaldehyde. Immunoprecipitations were performed overnight at 4 °C with 2 μg of anti-Cdx2 antibody (CDX2-88; BioGenex), nonimmunized mouse IgG whole molecule (sc-2025; Santa Cruz Biotechnology, Santa Cruz, CA), anti-Brm antibody (ab15597; Abcam), anti-BRG1 antibody (sc-17796; Santa Cruz), or nonimmunized rabbit IgG whole molecule (sc-2027; Santa Cruz). After reverse crosslinking, the obtained DNA was purified using phenol/chloroform extraction followed by ethanol precipitation. PCR amplification procedures detecting the HCR-Cdx, exon 1 and 2 of the *villin*, and the *CD44* promoter region using the purified DNA were described in the Supplementary materials and methods.

GST pull-down assay

Recombinant Cdx2 was expressed in *E. coli* (Rosetta2 strain) as a glutathione S-transferase (GST) fusion protein. ^{35}S-labeled subunits of SWI/SNF complex (Brm, BRG1, Ini1, BAF60a, and β-action) were synthesized in rabbit reticulocyte lysates (Promega) or wheat germ lysates (Promega). For the expression of GST-Cdx2, *Cdx2*



Fig. 2 – (A) Schematic representation of the human *villin* gene structure and sequences of the highly conserved regions harboring two putative Cdx binding sites (HCR-Cdx) in the *villin* promoter regions of six mammal species. In the human *villin* genomic sequence, the HCR-Cdx is located about 1.1 kb upstream of exon 1. The two consensus binding elements for the Cdx family of transcription factors are indicated by arrows. In the schema for the human *villin* gene, the three identified TSSs (including major TSS) are indicated, and the translation start ATG in exon 2 is double underlined. (B) Expression patterns of the *villin*, *Cdx2*, and *Cdx1* mRNAs in a panel of 32 human cancer cell lines. Twenty gastric cancer cell lines, 10 colorectal cell lines, and two non-gastrointestinal cell lines (HeLa-S3 and MDA-MB435) were analyzed by RT-PCR. The presence of Brm protein is denoted by the + and − symbols as in our previous reports [8,11].

cDNA excised from pMXs-Cdx2-IRES-puro was subcloned into the EcoRI site of pGEX-4T2 vector (GE Healthcare, Madison, WI). For the expression of other proteins, *Brm*, *BRG1*, *Ini1*, and *β-action* cDNA inserted into pBluescript-SK(+) (Stratagene) and *BAF60a* cDNA inserted into pOTB7 (Open Systems) were used. GST pull-down assay was performed as described previously [14] except that washing was performed 6 times rather than 4 times. SDS-PAGE was performed as described previously [14].

Nuclear extraction and immunoprecipitation

Nuclear extracts were prepared from SW480-Cdx2 cells (SW480 cells stably transduced with MuLV-based retrovirus vectors carrying *Cdx2* gene) as described previously. The nuclear extracts were incubated at 4 °C overnight with normal either anti-Brm (Abcam, ab15597) or normal rabbit IgG (Santa Cruz, sc-2027) in TNE buffer [10 mM Tris–HCl (pH 7.8), 1% NP40, 150 mM NaCl, and 1 mM EDTA] with 0.01 M PMSF and protease inhibitors. Protein A/G plus-agarose beads (40 μl) were then added, and samples were incubated at 4 °C for 1 h. The beads were collected and washed three times with TNE buffer, and bound protein complexes were analyzed by SDS/PAGE followed by western blotting using anti-Cdx2 antibody (BioGenex: CDX2-88).

Tumor samples

89 tumor samples (banked at the Fujita Health University School of Medicine, Aichi, Japan) were randomly selected from advanced gastric cancer patients and stained with anti-Cdx2 antibody. We selected 39 samples from this group in which immunoreactivity of Cdx2 was clearly evident. In this group of 39 tissue specimens (Table S1), we then analyzed the expression pattern of villin and Cdx2. The corresponding patients were aged from 37 to 92 years (a mean of 67.5 ± 11.0 years), and comprised 26 males and 13 females. The clinical stage distribution, according to the UICC (the International Union Against Cancer) classification, was as follows: I in 4 patients (10.3%), II in 7 patients (17.9%), III in 20 patients (51.3%), and IV in 8 patients (20.5%). This study was approved by the institutional ethical review board for human investigation at Fujita Health University.

Results

Detection of the major transcription start site for the human villin gene in gastrointestinal cells

In our recent study [8], we employed 5′-RACE analysis and detected a transcription start site (TSS) for the human *villin* gene, which differs from the previously reported site at 20 bp upstream from the ATG translation start codon [15]. By 5′-RACE, we here isolated two additional *villin* TSSs, which are closely located to our previous one (Fig. 1A). Using villin-positive NUGC-4 and villin-negative AZ-521 cells, we next performed the primer extension experiments, and two TSSs obtained from our 5′-RACE analysis were clearly detected (Fig. 1B). The longest transcript (shown in Fig. 1A) and the earlier reported TSS [15] were not detected in this analysis.

We additionally performed RT-PCR analysis of *villin* using the same cell lines. One fixed reverse primer (present in exon 6) and four forward primers were used (Fig. 1C), and these data were consistent with 5′-RACE results and with the predicted exon/intron structures. Genomic sequences from six mammal species were further compared, and the non-coding exon 1 we identified was found to be highly conserved (Fig. S1). Taken together, we concluded that the major TSS for the human *villin* gene in gut cells is the 5′-end cytosine residue of the second longest transcript (Figs. 1A, C).

A highly conserved region containing two putative Cdx binding sites (HCR-Cdx) is present in the promoter of the villin gene

To examine the transcriptional regulation of the *villin* gene, the genomic sequences upstream of its non-coding exons in six mammal species were screened using NCBI Blast2 Sequence [16] and Clustal_W [17]. About 1.1 kb upstream of our identified human *villin* TSS, there is a highly conserved region (Fig. 2A), within which was found a consensus binding element for the chicken *CdxA* homeobox gene, a homologue of the mammalian *Cdx1*, *Cdx2*, and *Cdx4* gene [18,19]. Among these Cdx proteins, Cdx1 and Cdx2 are essential for intestinal development and homeostasis [20], and Cdx2 is thought to play a very important role in the mammalian gut as a regulator of many genes such as *sucrase isomaltase* [21], *MUC2* [22], *KLF4* [23], *guanylyl cyclase C* [24], and *LI-cadherin* [18].

We next screened 32 human cell lines (20 gastric, 10 colorectal, and two non-gastrointestinal cells) for the expression of *villin*,



Fig. 3 – (A) Western blotting analysis of Cdx2 and β-actin (internal control) expression in SW480 cells virally transduced with pMXs-Cdx2-IRES-Puro (SW480-Cdx2), pMXs-IRES-Puro (SW480-IP), pMXs-Cdx1-IRES-Puro (SW480-Cdx1), or pMXs-Cdx4-IRES-Puro (SW480-Cdx4). The expression of *Cdx1*, *Cdx4*, *villin*, *LI-cadherin*, and *GAPDH* (internal control) was analyzed by RT-PCR. (B) Western blotting analysis of Cdx2 and β-actin expression in SW480 parental cells and established infectant SW480 cells expressing shRNAs targeting the *Cdx2* (shCdx2_1 and shCdx2_2) or *GFP* (shGFP) genes. The expression of *villin*, *LI-cadherin*, and *GAPDH* was analyzed by RT-PCR.

Cdx2, and *Cdx1*. As shown in Fig. 2B, many gastric and colorectal cells express *villin*, and in each case also express *Cdx2*, with two exceptions, KE-39 and WiDr. On the contrary, *Cdx1* expression is not as common in gastric and colorectal cancer cell lines. These expression patterns suggest that Cdx2 regulates the transcription of the *villin* gene. The non-gastrointestinal cell lines HeLa-S3 and MDA-MB435 were negative for both *villin* and *Cdx2* as expected.

Exogenous modulation of Cdx2 expression level affects the endogenous villin gene expression

We constructed a series of MuLV-based retrovirus vectors carrying either the *Cdx2*, *Cdx1*, or *Cdx4* gene, and transduced them individually into the SW480 colorectal cancer cell line. In the resulting stable SW480 transductants, *villin*, *LI-cadherin*, and *GAPDH* were analyzed by RT-PCR (Fig. 3A). *LI-cadherin*, whose expression is regulated by Cdx2 [18], was found to be strongly induced in SW480-Cdx2 cells, and marginally induced in SW480-Cdx1 cells. The *villin* gene response was very similar; a strong upregulation in SW480-Cdx2 cells but a weak induction in SW480-Cdx1 cells (Fig. 3A). No expression changes were detected in SW480-Cdx4 cells for either *LI-cadherin* or *villin*.

It is noteworthy that the endogenous Cdx2 protein expression levels were efficiently suppressed by exogenous Cdx1 expression, suggesting that Cdx1 protein negatively regulates *Cdx2* gene expression. This effect of Cdx1 upon *Cdx2* has been revealed also in previous reports of *Cdx1* knockout mice and *Cdx1* transgenic mice [25,26]. In SW480-Cdx1 cells, therefore, exogenous Cdx1 appears to act as a somewhat effective substitute for endogenous Cdx2 and thereby facilitate *villin* and *LI-cadherin* expression, although to a lesser extent.

We constructed additional retrovirus vectors carrying short-hairpin RNAs (shRNAs) that were designed to target two different regions of the *Cdx2* gene. These vectors were transduced into SW480 cells to obtain stable transfectants. Western blotting analysis revealed a drastic decrease of Cdx2 expression in SW480-shCdx2_1 cells and a moderate decrease in SW480-shCdx2_2 cells (Fig. 3B). To analyze the effects of Cdx2 upon endogenous *villin* and *LI-cadherin* expression, RT-PCR analyses were performed (Fig. 3B). *LI-cadherin* expression was found to be decreased in both the SW480-shCdx2_1 and SW480-shCdx2_2 transduced cells, but was more prominent in the former probably reflecting its greater knockdown efficiency of Cdx2. *Villin* expression was reduced in SW480-shCdx2_1 cells only, suggesting that Cdx2 knockdown in SW480-shCdx2_2 was



Fig. 4 – (A) Schematic representation of the human *villin* gene reporter constructs used in this study. HCR-Cdx is denoted by the grayish box, with + 1 assigned to the major 5′-end base of the *villin* cDNA sequence determined by both 5′-RACE and primer extension analysis. The nine predicted Cdx binding sites shown with scores were revealed using TFSEARCH programs (ver. 1.3). (B) Reporter analyses of a series of *villin* promoter constructs in parental SW480 cells and established SW480 cells expressing shRNAs targeting *Cdx2* (shCdx2_1 and shCdx2_2). Luciferase activities were measured at 48 h after transfections, and the data shown are the mean values of triplicate experiments, with the error bars correspond to the standard errors. (C) Reporter analyses of *villin* gene constructs in SW480 cells expressing shRNAs targeting *GFP*, *BRG1*, and *Brm*. 48 h after transfection of each reporter plasmid, luciferase activities were measured. Data shown are the mean values of triplicate experiments, with the error bars corresponding to the standard errors.

insufficient to suppress the *villin* transcription. From these results, we conclude that the transcription factor Cdx2 plays essential roles in *villin* expression in intestinal cells.

Since we have previously reported that Brm is required for *villin* expression in gastric cancer cells [8], we tested whether the loss of *Cdx2* expression would lead to a down-regulation of *Brm* expression and *vice versa*. Using SW480 and AGS cells stably expressing shCdx2_1, shCdx2_2, shBrm, shBRG1, shIni1, or shGFP, we performed western blotting for Cdx2 and Brm. However, no reciprocal effects could be detected in either cell line; the expression of these two genes seems to be mutually independent (Fig. S2).

The HCR-Cdx in the villin promoter is critical for both the Cdx2-dependent and Brm-dependent expression of villin

To test whether the highly conserved region of the *villin* promoter containing two putative Cdx2 binding sequences (HCR-Cdx) is important for intestinal *villin* expression, we designed a series of reporter constructs for this region and performed luciferase assays in SW480 cells (Fig. 4A). As shown in Fig. 4B, SW480 cells transfected with constructs harboring HCR-Cdx (BX and III) showed significantly higher levels of luciferase activity compared with constructs in which this region is deleted (I and II). These data imply that *villin* transcription is efficiently activated through the HCR-Cdx of its promoter.

When similar experiments were performed using the stable transductants, SW480-shCdx2_1 and SW480-shCdx2_2 (Fig. 3B), a strong decrease in reporter activity was observed for the BX and III reporter constructs (Fig. 4B). These data indicate that transactivation of the *villin* gene via HCR-Cdx strongly depends on Cdx2 expression. Compared with the BX and III reporters, reporter I, which lacks HCR-Cdx, also showed slight dependency to shCdx2_1 and shCdx2_2. This might be explained by several Cdx consensus sequences present between −1106 and −112 of the *villin* promoter (Fig. 4A), which have lower binding scores and are not conserved in mammals.

Using the BX and III reporters, we further examined the effects of Brm and BRG1 knockdown in SW480 cells. For both reporters, shBrm, but not shBRG1, efficiently suppressed luciferase activity (Fig. 4C), implying that intestinal *villin* gene expression is dependent on Brm as well as Cdx2, consistent with our previous report [8].



Fig. 5 – Immunostaining of Cdx2 (A, B), villin (C, D), and Brm (E) in sequential sections of non-malignant gastric mucosa, in which normal gastric mucosa (villin negative) and intestinal metaplasia (villin positive) coexist. (B) and (D) are magnified images corresponding to the framed areas in panels A and C, respectively. Cdx2 is an intranuclear protein, whereas villin is expressed in the cytoplasm and/or on the brush border structure of the cellular membrane. Scale bars, 500 μm (A, C, E); 100 μm (B, D).

The expression of Cdx2 and villin is tightly coupled in gastrointestinal tissues

It has been previously reported that the expression of Cdx2 in normal adult tissues is mostly restricted to the epithelial cells of the small and large intestine [27]. It was also reported in an earlier study that Cdx2 and Cdx1 are almost always induced in gastric intestinal metaplasia [28]. Additionally, from previous analysis of multiple human tumor samples, it has been observed that adenocarcinomas of intestinal origin are mostly Cdx2-positive [7]. These accumulative findings in vivo suggest that the distribution of Cdx2 is similar to that of villin, which supports the results of our biochemical analysis that the *villin* gene is regulated by Cdx2. To more precisely evaluate whether a correlation exists between the expression of Cdx2 and villin, we performed an immunohistochemical survey at the resolution of a single cell.

Normal gastric mucosa expresses neither Cdx2 nor villin, but both proteins are detectable in a variety of stomach disorders [28]. We thus speculated that gastric tissues would be the most suitable for evaluating the correlation between Cdx2 and villin, and analyzed 39 gastric cancer tissue samples, in which immunoreactivity against Cdx2 was clearly evident (Table S1). As both normal gastric mucosa and non-malignant intestinal metaplasia were present on all of these samples, we first evaluated the areas harboring intestinal metaplastic changes. In all of the 39 cases examined, the expression patterns of villin and Cdx2 were found to be completely identical at a single cell resolution (Figs. 5A–D). As we previously reported [8], Brm was detected in normal gastric mucosa and non-malignant intestinal metaplasia as well as mesenchymal cells (Fig. 5E). The expression patterns of these proteins in gastric cancer tissues were then evaluated, and we again observed a perfect coupling of both proteins at a single cell resolution (Figs. 6A–D). These clear co-expression patterns *in vivo* strongly support our contention that Cdx2 is a principal regulator of *villin* expression. As shown in Figs. 6E and F, all the malignant cells were found to express Brm, which is consistent with the idea that both Cdx2 and Brm are required for *villin* expression.

It is noteworthy that *villin* is also expressed in some cells that are not of gastrointestinal origin, including those of the kidney proximal tubules, intrahepatic bile ducts, and pancreatic ducts [1]. To test whether Cdx2 is always required for the *villin* expression, sequential sections of proximal tubules from a normal kidney were immunostained for both Cdx2 and villin (Fig. S3). The results clearly indicated that *villin* expression does not always require Cdx2 expression in these non-gastrointestinal cells.



Fig. 6 – Immunostaining of Cdx2 (A, B), villin (C, D), and Brm (E, F) in sequential sections of primary gastric cancers (moderately differentiated tubular adenocarcinomas). (B), (D), and (F) are magnified images corresponding to the framed areas in panels A, C, and E respectively. Scale bars, 500 μm (A, C, E); 100 μm (B, D, F).

Cdx2 directly binds to several subunits of the SWI/SNF chromatin remodeling complex

Considering the cooperative activity between Cdx2 and Brm (Brm-type SWI/SNF complex) in the regulation of *villin* expression, we examined whether Cdx2 protein directly interacts with Brm or other components of the SWI/SNF complex. Brm, BRG1, BAF60a, Ini1 and β-actin proteins were synthesized *in vitro*, and each was mixed with a GST-Cdx2 fusion protein. As shown in Fig. 7A, the GST pull-down assay clearly demonstrated that Brm strongly binds to Cdx2. BRG1, an alternative catalytic subunit of SWI/SNF complex, also showed a similar binding affinity to Cdx2, although this protein does not appear to be required for intestinal *villin* expression, as judged by our current findings (Fig. 4C) and also our previous report [8]. With regard to the three other subunits of the SWI/SNF complex, Ini1 and BAF60a can directly bind to Cdx2 protein, whereas β-actin cannot (Fig. 7A). These results suggest that SWI/SNF complex can interact with Cdx2 protein at multiple points on its surface.

Using the nuclear extracts from SW480-Cdx2 cells, we further performed the coimmunoprecipitation assay. As shown in Fig. 7B, Cdx2 protein was efficiently detected by western blotting in the immunoprecipitates of anti-Brm antibody. From this result, we concluded that Brm binds to Cdx2 *in vivo*.

Cdx2 and Brm interact with the villin promoter region

As both Brm and Cdx2 are required for intestinal *villin* expression, we tested whether these two proteins associate with the *villin* promoter. ChIP assays using SW480 cells were performed, and the HCR-Cdx, and in a lesser extent the exon 1 region of the *villin* gene, were efficiently coimmunoprecipitated with either Cdx2 or Brm (Fig. 7C). This indicates that both Cdx2 and Brm are present around the HCR-Cdx motif in the *villin* promoter.



Fig. 7 – (A) The binding of Cdx2 to subunits of the SWI/SNF complex analyzed by GST pull-down. Purified GST-Cdx2 and GST (control) proteins attached to GSH-Sepharose beads were prepared, and their binding to Brm, BRG1, Ini1, BAF60a, and β-actin (synthesized *in vitro* in the presence of [^{35}S]methionine) was analyzed. (B) An immunoprecipitation assay using nuclear extracts derived from SW480-Cdx2 cells (SW480 cells stably transduced with MuLV-based retrovirus vectors carrying *Cdx2* gene). Immunoprecipitates with anti-Brm antibody or non-specific rabbit IgG (control) were analyzed by western blotting using anti-Cdx2 antibody. (C, D) ChIP analyses of the human *villin* gene in SW480 (C) or HT-29 cells (D). For immunoprecipitations, anti-Cdx2 antibody, nonimmunized mouse IgG whole molecule, anti-Brm antibody, anti-BRG1 antibody, and nonimmunized rabbit IgG whole molecule were used. PCR was performed with primers that recognize the HCR-Cdx, exons 1 and 2 of the human *villin* gene, and the promoter region of the human *CD44* gene.

We performed another series of ChIP analysis using colorectal HT-29 cells, which are reported to express *CD44* [29], a target of both the Brm- and BRG1-type SWI/SNF complex [9,10]. As shown in Fig. 7D, *CD44* promoter was detected in the immunoprecipitates of Brm and BRG1 antibodies as expected, but not in those of Cdx2 antibodies. In contrast, the HCR-Cdx region was efficiently coimmunoprecipitated with Cdx2 and Brm as well as BRG1. From these results, we concluded that Cdx2 and Brm interact with the *villin* promoter region in gastrointestinal cells.

Discussion

Cdx2 and the Brm-type SWI/SNF complex act cooperatively to regulate villin expression in gastrointestinal cells

Our ChIP analyses revealed that in human gastrointestinal cells, Cdx2 and Brm are present around the HCR-Cdx in the *villin* promoter (Figs. 7B, C). Luciferase reporter assays further suggested that the Cdx binding sites present in the HCR-Cdx region are responsible for the Cdx2- and Brm-dependent transactivation of human *villin* (Fig. 4). These results indicate that Cdx2 would recruit the Brm-type SWI/SNF complex to facilitate the stable expression of the *villin* gene. Through the direct binding of several subunits (Fig. 7A), Cdx2 is likely to efficiently recruit the SWI/SNF complex in the process of transactivation of target genes, like such other transcription factors as AP-1 [30], CREB [31], C/EBP-β [32], MyoD [33], c-Myc [34,35], glucocorticoid receptor [36,37], estrogen receptor [38], androgen receptor [39], GATA-1 [40], SP-1 [41], p54nrb [14], and so on.

The BRG1-type SWI/SNF complex does not seem to be required for the *villin* gene expression (Fig. 4C). It is of note, however, that Brm knockout (Brm (−/−)) mouse is alive without an apparent phenotype [42]. We believe that in cells which completely lack Brm, BRG1 would compensate for it in a very low efficiency. It should be pointed out that BRG1 can also bind Cdx2 *in vitro* and is recruited to the *villin* promoter (Figs. 7A and B). The molecular mechanisms for preferential transactivation activity of the Brm-type SWI/SNF complex remain to be elucidated. Our present data show that Cdx2 regulates the *villin* gene in gastrointestinal cells.

It is noteworthy in this regard, however, that in non-intestinal tissues such as renal proximal tubules, *villin* expression is not accompanied by Cdx2 expression (Fig. S3). This suggests that other transcription factors unique to non-intestinal tissues can substitute for Cdx2 and fully activate the *villin* gene expression. Among the 30 gastrointestinal tumor cell lines examined in our current study, we observed two villin-positive but Cdx2-negative cell lines, WiDr and KE-39 (Fig. 2B). In these malignant cells, such substitutive transcription factors other than Cdx2 might be ectopically expressed.

Cdx2 should be one of the key molecules underlying the association between the Brm-deficiency and the histologic features of gastric cancer

In our previous study, we showed that loss of Brm expression is frequent in gastric cancer, and that the Brm-deficiency correlates well with undifferentiated status of gastric malignancy [8]. We also found the involvement of Brm in the expression of *villin*, which is an important gut differentiation marker. It is apparent, however, that villin alone cannot account for the relationship between Brm expression and the gastric cancer classification. Therefore, it is of considerable interest that Cdx2 can recruit the Brm-type SWI/SNF complex to the *villin* promoter, through its direct binding to several subunits of the SWI/SNF complex. It is intuitive that Cdx2 cooperates with the Brm-type SWI/SNF complex to regulate not only the *villin* gene but also many genes important for intestinal differentiation, maintenance, function, and structure [18,20–24]. We are convinced that Cdx2 is a key linker between the loss of Brm and undifferentiated status of gastric cancer.

Acknowledgments

We thank Dr. Kazuya Shiogama (1st Department of Pathology, Fujita Health University School of Medicine) for assistance with the immunohistochemistry analyses. We also thank Dr. Mitsue Yamamichi-Nishina for assistance with preparing this manuscript. This work was supported in part by a Grant-in-Aid for Scientific Research on Priority Areas from the Ministry of Education, Cultures, Sports, Science, and Technology of Japan; and was also supported in part by Strategic cooperation to control emerging and reemerging infections funded by the Special Coordination Funds for Promoting Science and Technology of Ministry of Education, Culture, Sports, Science and Technology (MEXT).

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.yexcr.2009.01.006.

REFERENCES

[1] R. Moll, S. Robine, B. Dudouet, D. Louvard, Villin: a cytoskeletal protein and a differentiation marker expressed in some human adenocarcinomas, Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 54 (1987) 155–169.
[2] D. Pinto, S. Robine, F. Jaisser, F.E. El Marjou, D. Louvard, Regulatory sequences of the mouse villin gene that efficiently drive transgenic expression in immature and differentiated epithelial cells of small and large intestines, J. Biol. Chem. 274 (1999) 6476–6482.
[3] K.I. Pinson, L. Dunbar, L. Samuelson, D.L. Gumucio, Targeted disruption of the mouse villin gene does not impair the morphogenesis of microvilli, Dev. Dyn. 211 (1998) 109–121.
[4] S. Robine, C. Huet, R. Moll, C. Sahuquillo-Merino, E. Coudrier, A. Zweibaum, D. Louvard, Can villin be used to identify malignant and undifferentiated normal digestive epithelial cells? Proc. Natl. Acad. Sci. U. S. A. 82 (1985) 8488–8492.
[5] K. Boller, M. Arpin, E. Pringault, P. Mangeat, H. Reggio, Differential distribution of villin and villin MRNA in mouse intestinal epithelial cells, Differentiation 39 (1988) 51–57.
[6] S. Kumble, M.B. Omary, L.F. Fajardo, G. Triadafilopoulos, Multifocal heterogeneity in villin and Ep-CAM expression in Barrett's esophagus, Int. J. Cancer 66 (1996) 48–54.
[7] R.W. Werling, H. Yaziji, C.E. Bacchi, A.M. Gown, CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas, Am. J. Surg. Pathol. 27 (2003) 303–310.
[8] N. Yamamichi, K. Inada, M. Ichinose, M. Yamamichi-Nishina, T. Mizutani, H. Watanabe, K. Shiogama, M. Fujishiro, T. Okazaki, N.

Yahagi, T. Haraguchi, S. Fujita, Y. Tsutsumi, M. Omata, H. Iba, Frequent loss of Brm expression in gastric cancer correlates with histologic features and differentiation state, Cancer Res. 67 (2007) 10727–10735.
[9] F. Banine, C. Bartlett, R. Gunawardena, C. Muchardt, M. Yaniv, E.S. Knudsen, B.E. Weissman, L.S. Sherman, SWI/SNF chromatin-remodeling factors induce changes in DNA methylation to promote transcriptional activation, Cancer Res. 65 (2005) 3542–3547.
[10] M. Yamamichi-Nishina, T. Ito, T. Mizutani, N. Yamamichi, H. Watanabe, H. Iba, SW13 cells can transition between two distinct subtypes by switching expression of BRG1 and Brm genes at the post-transcriptional level, J. Biol. Chem. 278 (2003) 7422–7430.
[11] N. Yamamichi, M. Yamamichi-Nishina, T. Mizutani, H. Watanabe, S. Minoguchi, N. Kobayashi, S. Kimura, T. Ito, N. Yahagi, M. Ichinose, M. Omata, H. Iba, The Brm gene suppressed at the post-transcriptional level in various human cell lines is inducible by transient HDAC inhibitor treatment, which exhibits antioncogenic potential, Oncogene 24 (2005) 5471–5481.
[12] T. Mizoshita, T. Tsukamoto, H. Nakanishi, K. Inada, N. Ogasawara, T. Joh, M. Itoh, Y. Yamamura, M. Tatematsu, Expression of Cdx2 and the phenotype of advanced gastric cancers: relationship with prognosis, J. Cancer Res. Clin. Oncol. 129 (2003) 727–734.
[13] S. Morita, T. Kojima, T. Kitamura, Plat-E: an efficient and stable system for transient packaging of retroviruses, Gene Ther. 7 (2000) 1063–1066.
[14] T. Ito, H. Watanabe, N. Yamamichi, S. Kondo, T. Tando, T. Haraguchi, T. Mizutani, K. Sakurai, S. Fujita, T. Izumi, T. Isobe, H. Iba, Brm transactivates the telomerase reverse transcriptase (TERT) gene and modulates the splicing patterns of its transcripts in concert with p54(nrb), Biochem. J. 411 (2008) 201–209.
[15] S. Robine, C. Sahuquillo-Merino, D. Louvard, E. Pringault, Regulatory sequences on the human villin gene trigger the expression of a reporter gene in a differentiating HT29 intestinal cell line, J. Biol. Chem. 268 (1993) 11426–11434.
[16] T.A. Tatusova, T.L. Madden, BLAST 2 Sequences, a new tool for comparing protein and nucleotide sequences, FEMS Microbiol. Lett. 174 (1999) 247–250.
[17] J.D. Thompson, D.G. Higgins, T.J. Gibson, CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice, Nucleic Acids Res. 22 (1994) 4673–4680.
[18] T. Hinoi, P.C. Lucas, R. Kuick, S. Hanash, K.R. Cho, E.R. Fearon, CDX2 regulates liver intestine-cadherin expression in normal and malignant colon epithelium and intestinal metaplasia, Gastroenterology 123 (2002) 1565–1577.
[19] M.S. Hwang, Y.S. Kim, N.H. Choi, J.H. Park, E.J. Oh, E.J. Kwon, M. Yamaguchi, M.A. Yoo, The caudal homeodomain protein activates *Drosophila* E2F gene expression, Nucleic Acids Res. 30 (2002) 5029–5035.
[20] R.J. Guo, E.R. Suh, J.P. Lynch, The role of Cdx proteins in intestinal development and cancer, Cancer Biol. Ther. 3 (2004) 593–601.
[21] E. Suh, L. Chen, J. Taylor, P.G. Traber, A homeodomain protein related to caudal regulates intestine-specific gene transcription, Mol. Cell. Biol. 14 (1994) 7340–7351.
[22] P. Mesquita, N. Jonckheere, R. Almeida, M.P. Ducourouble, J. Serpa, E. Silva, P. Pigny, F.S. Silva, C. Reis, D. Silberg, I. Van Seuningen, L. David, Human MUC2 mucin gene is transcriptionally regulated by Cdx homeodomain proteins in gastrointestinal carcinoma cell lines, J. Biol. Chem. 278 (2003) 51549–51556.
[23] D.T. Dang, C.S. Mahatan, L.H. Dang, I.A. Agboola, V.W. Yang, Expression of the gut-enriched Kruppel-like factor (Kruppel-like factor 4) gene in the human colon cancer cell line RKO is dependent on CDX2, Oncogene 20 (2001) 4884–4890.
[24] J. Park, S. Schulz, S.A. Waldman, Intestine-specific activity of the human guanylyl cyclase C promoter is regulated by Cdx2, Gastroenterology 119 (2000) 89–96.
[25] M.A. Crissey, R.J. Guo, F. Fogt, H. Li, J.P. Katz, D.G. Silberg, E.R. Suh, J.P. Lynch, The homeodomain transcription factor Cdx1 does not behave as an oncogene in normal mouse intestine, Neoplasia 10 (2008) 8–19.
[26] C. Bonhomme, A. Calon, E. Martin, S. Robine, A. Neuville, M. Kedinger, C. Domon-Dell, I. Duluc, J.N. Freund, Cdx1, a dispensable homeobox gene for gut development with limited effect in intestinal cancer, Oncogene 27 (2008) 4497–4502.
[27] D.G. Silberg, G.P. Swain, E.R. Suh, P.G. Traber, Cdx1 and cdx2 expression during intestinal development, Gastroenterology 119 (2000) 961–971.
[28] R. Almeida, E. Silva, F. Santos-Silva, D.G. Silberg, J. Wang, C. De Bolos, L. David, Expression of intestine-specific transcription factors, CDX1 and CDX2, in intestinal metaplasia and gastric carcinomas, J. Pathol. 199 (2003) 36–40.
[29] A.C. Woodman, M. Sugiyama, K. Yoshida, T. Sugino, A. Borgya, S. Goodison, Y. Matsumura, D. Tarin, Analysis of anomalous CD44 gene expression in human breast, bladder, and colon cancer and correlation of observed mRNA and protein isoforms, Am. J. Pathol. 149 (1996) 1519–1530.
[30] T. Ito, M. Yamauchi, M. Nishina, N. Yamamichi, T. Mizutani, M. Ui, M. Murakami, H. Iba, Identification of SWI.SNF complex subunit BAF60a as a determinant of the transactivation potential of Fos/Jun dimers, J. Biol. Chem. 276 (2001) 2852–2857.
[31] P.B. Dallas, I.W. Cheney, D.W. Liao, V. Bowrin, W. Byam, S. Pacchione, R. Kobayashi, P. Yaciuk, E. Moran, p300/CREB binding protein-related protein p270 is a component of mammalian SWI/SNF complexes, Mol. Cell. Biol. 18 (1998) 3596–3603.
[32] E. Kowenz-Leutz, A. Leutz, A C/EBP beta isoform recruits the SWI/SNF complex to activate myeloid genes, Mol. Cell 4 (1999) 735–743.
[33] I.L. de la Serna, K.A. Carlson, A.N. Imbalzano, Mammalian SWI/SNF complexes promote MyoD-mediated muscle differentiation, Nat. Genet. 27 (2001) 187–190.
[34] S.W. Cheng, K.P. Davies, E. Yung, R.J. Beltran, J. Yu, G.V. Kalpana, c-MYC interacts with INI1/hSNF5 and requires the SWI/SNF complex for transactivation function, Nat. Genet. 22 (1999) 102–105.
[35] J. Park, M.A. Wood, M.D. Cole, BAF53 forms distinct nuclear complexes and functions as a critical c-Myc-interacting nuclear cofactor for oncogenic transformation, Mol. Cell. Biol. 22 (2002) 1307–1316.
[36] T.M. Fletcher, N. Xiao, G. Mautino, C.T. Baumann, R. Wolford, B.S. Warren, G.L. Hager, ATP-dependent mobilization of the glucocorticoid receptor during chromatin remodeling, Mol. Cell. Biol. 22 (2002) 3255–3263.
[37] C. Muchardt, M. Yaniv, A human homologue of *Saccharomyces cerevisiae* SNF2/SWI2 and *Drosophila* brm genes potentiates transcriptional activation by the glucocorticoid receptor, EMBO J. 12 (1993) 4279–4290.
[38] B. Belandia, R.L. Orford, H.C. Hurst, M.G. Parker, Targeting of SWI/SNF chromatin remodelling complexes to estrogen-responsive genes, EMBO J. 21 (2002) 4094–4103.
[39] T.W. Marshall, K.A. Link, C.E. Petre-Draviam, K.E. Knudsen, Differential requirement of SWI/SNF for androgen receptor activity, J. Biol. Chem. 278 (2003) 30605–30613.
[40] H. Im, J.A. Grass, K.D. Johnson, S.I. Kim, M.E. Boyer, A.N. Imbalzano, J.J. Bieker, E.H. Bresnick, Chromatin domain activation via GATA-1 utilization of a small subset of dispersed GATA motifs within a broad chromosomal region, Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 17065–17070.
[41] H. Ding, A.M. Benotmane, G. Suske, D. Collen, A. Belayew, Functional interactions between Sp1 or Sp3 and the helicase-like transcription factor mediate basal expression from the human plasminogen activator inhibitor-1 gene, J. Biol. Chem. 274 (1999) 19573–19580.
[42] J.C. Reyes, J. Barra, C. Muchardt, A. Camus, C. Babinet, M. Yaniv, Altered control of cellular proliferation in the absence of mammalian brahma (SNF2alpha), EMBO J. 17 (1998) 6979–6991.

Locked Nucleic Acid *In situ* Hybridization Analysis of miR-21 Expression during Colorectal Cancer Development

Nobutake Yamamichi,[1,2] Ryoichi Shimomura,[3] Ken-ichi Inada,[3] Kouhei Sakurai,[1] Takeshi Haraguchi,[1] Yuka Ozaki,[1] Shuji Fujita,[1] Taketoshi Mizutani,[1] Chihiro Furukawa,[1] Mitsuhiro Fujishiro,[2] Masao Ichinose,[4] Kazuya Shiogama,[3] Yutaka Tsutsumi,[3] Masao Omata,[2] and Hideo Iba[1]

Abstract **Purpose:** To better understand microRNA miR-21 function in carcinogenesis, we analyzed miR-21 expression patterns in different stages of colorectal cancer development using *in situ* hybridization (ISH).

Experimental Design: Locked nucleic acid (LNA)/DNA probes and a biotin-free tyramide signal amplification system were used in ISH analyses of miRNA expression. Conditions for specific detection of miR-21 were determined using human cell lines and miR-21–expressing lentiviral vectors. Expression was determined in 39 surgically excised colorectal tumors and 34 endoscopically resected colorectal polyps.

Results: In the surgical samples, miR-21 expression was much higher in colorectal cancers than in normal mucosa. Strong miR-21 expression was also observed in cancer-associated stromal fibroblasts, suggesting miR-21 induction by cancer-secreted cytokines. Protein expression of PDCD4, a miR-21 target, was inversely correlated with miR-21 expression, confirming that miR-21 is indeed a negative regulator of PDCD4 *in vivo*. In the endoscopic samples, miR-21 expression was very high in malignant adenocarcinomas but was not elevated in nontumorigenic polyps. Precancerous adenomas also frequently showed miR-21 up-regulation.

Conclusion: Using the LNA-ISH system for miRNA detection, miR-21 was detectable in precancerous adenomas. The frequency and extent of miR-21 expression increased during the transition from precancerous colorectal adenoma to advanced carcinoma. Expression patterns of miR-21 RNA and its target, tumor suppressor protein PDCD4, were mutually exclusive. This pattern may have clinical application as a biomarker for colorectal cancer development and might be emphasized by self-reinforcing regulatory systems integrated with the *miR-21* gene, which has been previously shown in cell culture.

Authors' Affiliations: [1]Division of Host-Parasite Interaction, Department of Microbiology and Immunology, Institute of Medical Science, and [2]Department of Gastroenterology, Faculty of Medicine, University of Tokyo, Tokyo, Japan; [3]First Department of Pathology, Fujita Health University School of Medicine, Aichi, Japan; and [4]Second Department of Internal Medicine, Wakayama Medical College, Wakayama, Japan

Received 12/22/08; revised 3/30/09; accepted 3/31/09; published OnlineFirst 6/9/09.

Grant support: Grant-in-Aid for Scientific Research on Priority Areas from the Ministry of Education, Cultures, Sports, Science, and Technology (MEXT) of Japan, and in part by Strategic cooperation to control emerging and reemerging infections funded by the Special Coordination Funds for Promoting Science and Technology of MEXT.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: Supplementary data for this article are available at Clinical Cancer Research Online (http://clincancerres.aacrjournals.org/).

Requests for reprints: Hideo Iba, Division of Host-Parasite Interaction, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, 4-6-1, Shirokanedai Minato-ku, Tokyo 108-8639, Japan. Phone: 81-3-5449-5730; Fax: 81-3-5449-5449; E-mail: iba@ims.u-tokyo.ac.jp.

© 2009 American Association for Cancer Research.

doi:10.1158/1078-0432.CCR-08-3257

Novel mechanisms of human gene regulation mediated by microRNAs (miRNA) have recently been established (1). MiRNAs control gene expression at the posttranscriptional level by targeting mRNAs for translational repression or mRNA degradation (1). Evidence is accumulating that many miRNAs are differentially regulated in normal development and cancers, and that deregulation of specific miRNAs may contribute to human cancer development and progression (1). To better understand the molecular mechanisms that regulate miRNA gene expression, our group has recently developed an algorithm to predict the promoters of human miRNA genes that are likely to be involved in evolutionarily conserved regulatory systems (2). Using this algorithm, we predicted 59 putative miRNA gene promoter regions, one of which was the *miR-21* miRNA promoter. Because high miR-21 expression levels have been reported in various malignancies, including breast cancer (3–5), pancreatic cancer (3, 6, 7), cholangiocarcinoma (8), hepatocellular carcinoma (9), brain tumor (10), leukemia (11, 12), cervical cancer (13), ovarian cancer (14), colorectal cancer (3, 15), prostate cancer (3), lung cancer (3), and gastric cancer (3), we concentrated on miR-21 analysis. Our biochemical analyses

Translational Relevance

To better understand microRNA (miRNA) function in carcinogenesis, sensitive and reproducible methods for *in situ* hybridization (ISH) are needed. For experimental analysis, we have chosen analysis of miR-21 expression during the process of colorectal cancer development, and strictly determined conditions for specific detection of miR-21 using several human cell lines and miR-21–expressing lentiviral vectors. ISH analysis of miRNA expression levels was finally established with locked nucleic acid (LNA)/DNA probes and biotin-free tyramide signal amplification system, which is finally applicable to formalin-fixed paraffin-embedded clinical samples. The established LNA-ISH system for miRNA detection showed that elevation of miR-21 becomes detectable from precancerous adenomas, and the extent and frequency of miR-21 expression increase during the colorectal canceration from precancerous adenoma to advanced carcinoma. Mutually exclusive expression patterns between miR-21 RNA and its target, tumor suppression protein PDCD4, in adenocarcinomas and precancerous adenomas will have a potential clinical application as a biomarker for colorectal cancer development.

confirmed that the *miR-21* promoter predicted by the algorithm was correct (2). Transcription of primary miR-21 transcripts (pri-mir-21) was initiated 30 bp downstream of the promoter TATA box. Other evolutionally conserved regulatory elements present in the miR-21 promoter included the binding sites of activator protein (AP-1), Ets/PU.1, SP1, CCAAT/enhancer binding protein-α, nuclear factor I (NFI), serum response factor, p53, and signal transducer and activator of transcription 3. We further showed that phorbol 12-myristate 13-acetate activated miR-21 transcription through the several AP-1 and Ets/PU.1 binding sites in the miR-21 promoter, and also showed that miR-21 was induced during macrophage differentiation of HL-60 cells (16). Therefore, we hypothesized that increased miR-21 expression, which has been validated in many cancers, may reflect elevated tumor cell AP-1 activity. We also identified the negative transcriptional regulator nuclear factor I-B (NFIB) as a target for miR-21 regulation (16). Because the *miR-21* promoter contains an NFIB binding site and NFIB efficiently suppresses AP-1–dependent miR-21 transactivation, we concluded that a double-negative feedback loop consisting of miR-21, NFIB, and the *miR-21* promoter could self-reinforce miR-21 expression (16).

Several other miR-21 targets have also been suggested such as *RECK* (17), *Sprouty2* (18), *PTEN* (8, 9), *TPM1* (19), and *PDCD4* (20–23). Tumor suppressor PDCD4 is reported to suppress protein synthesis (24, 25) through cytoplasmic binding of eIF4A and is also known to inhibit several transcription factors, including AP-1 (26, 27), SP1 (28), and β-catenin (26). Because DNA binding sites for some of these factors are present in miR-21 promoters, PDCD4 might also contribute to the down-regulation of miR-21 expression through double-negative feedback regulation. Indeed, it was recently reported that in Ras-induced cellular transformation of a rat thyroid cell line, PDCD4 reduces miR-21 activity, at least partly, by suppressing AP-1 activity (29). However, at this moment, there is even no clear proof that PDCD4 is a target of miR-21 *in vivo* because of the lack of efficient tools to detect miR-21 expression in a single-cell resolution.

As a first step toward understanding mechanisms regulating *miR-21* expression *in vivo*, we examined miR-21 expression patterns during the cancer development. Colorectal tumors were chosen for the experimental analyses because the clinical and histologic features of colorectal cancers are relatively simple compared with other malignancies, and most of colorectal cancers are thought to develop from precancerous adenomas (30). For this purpose, we established a sensitive and stable *in situ* hybridization (ISH) method using formalin-fixed, paraffin-embedded (FFPE) tissues. Experimental results indicate that the frequency and extent of miR-21 expression increase during colorectal cancer progression from precancerous adenoma to advanced carcinoma.

Materials and Methods

Human cell lines. HEK293 (originated from embryonic kidney), HeLa (cervical carcinoma), MDA-MB435 (breast ductal carcinoma), PA-1 (embryonic carcinoma), NCC-IT (embryonic carcinoma), A427 (non small cell lung carcinoma), G401 (rhabdoid tumor), SW620 (colorectal adenocarcinoma), and AZ521 (gastric cancer) cells were maintained at 37°C in high-glucose DMEM supplemented with 10% FCS (Gibco/Invitrogen).

Locked nucleic acid–modified oligonucleotide probes. Locked nucleic acid (LNA)–modified oligonucleotide probes labeled with FITC at their 3′-ends were obtained from Molecular Biology of ThermoElectron GmbH. The sequences of miR-21 probe and the scramble control probe for a negative control were 5′-TLcAALcATLcAGLtCTLgATLaAGLcTA-3′ and 5′-CLaTTLaATLgTCLgGALcAALcTCLaAT-3′, respectively. La, Lt, Lc, and Lg were LNA monomers corresponding to the bases A, T, C, and G, respectively.

ISH with LNA-modified oligonucleotide probes. Five-micrometer-thin sections of FFPE tissues adhered to glass slides were deparaffinized in three consecutive xylene baths for 1 min each, followed by 1 min each in serial dilutions of ethanol (100%, 100%, 95%, 95%) and three changes of diethyl pyrocarbonate–treated water. Slides were then immersed in 0.3% H_2O_2 for 30 min at room temperature, washed thrice with diethyl pyrocarbonate–treated water, digested with 400 μg/mL proteinase K (Roche) at 37°C for 15 min, washed thrice with diethyl pyrocarbonate–treated water, submerged in 95% ethanol for 1 min, and air-dried completely. Slides were then hybridized in incubation chambers overnight at 37°C in an oven, using 0.2 μmol/L LNA–modified probes diluted with mRNA ISH solution (DAKO). After hybridization, slides were rinsed thrice in 0.5× SSC, washed for 30 min at 50°C in 0.5× SSC/0.1% Brij35 (Sigma), and rinsed twice in TBS. An anti-FITC horseradish peroxidase–conjugated antibody (DAKO, P5100) at 1:100 dilution in TBS/1% bovine serum albumin was applied to the slides for 60 min at room temperature, followed by three washes in TBS/0.1% Tween 20 (TBS-T). For amplification of antibody signals, FITC-conjugated phenol (fluorescyl-tyramide, DAKO, K1497) was applied to the slides for 30 min at room temperature, followed by three washes in TBS-T. Finally, an anti-FITC antibody conjugated to horseradish peroxidase (DAKO, K1497) was added to the slides for 30 min at room temperature, followed by three washes in TBS-T. The reaction products were visualized using a 50 mg/dL 3,3′-diaminobenzidine tetrahydrochloride solution containing 0.003% hydrogen peroxide.

Immunohistochemical staining. Deparaffinization, endogenous peroxidase inactivation, antigen retrieval of FFPE clinical tissues, and

immunostaining with anti-PDCD4 (ab51495, Abcam) antibody were done as described previously (31). The immunostained sections were evaluated independently by two pathologists in conjunction with the H&E-stained sections from the same lesions.

Lentivirus vectors. For the polymerase II–driven (SV40 promoter) vector, a part of pri-miR-21 sequence (from −6 bp to +65 bp of the 5′-end of mature miR-21 sequence) was inserted between the *Bam*HI and *Eco*RI sites of pLSP (22) to generate pLSP-pre-mir21_short. For the polymerase III–driven (U6 promoter) vector, the mouse U6 promoter and a part of the pri-miR-21 sequence (from −57 bp to +115 bp of the 5′-end of mature miR-21 sequence) were inserted into the *Bam*HI and *Eco*RI sites of pLSP to generate pLSP-mU6-pre-mir21_long. Sequences of synthetic oligonucleotide pairs for shCre (targeting Cre-recombinase of P1phage) and shU3-12 (targeting part of MuLV-LTR) were described previously. They were inserted into pLPS as described above to generate pLPS-shCre and pLSP-shU3-12 (32), respectively, and used for the negative controls. Vesicular stomatitis virus-G pseudotyped lentiviral vectors were produced using the ViraPower Lentiviral Expression System (Invitrogen) according to the manufacturer's instructions.

Virus transduction and protein analysis. HEK293 cells were transduced with vesicular stomatitis virus-G pseudotyped vectors at multiplicity of infection of 1 to 2 and selected with puromycin for 1 wk. About 1 wk after the end of selection, cells were disrupted for total protein preparation. Western blotting analysis with anti-PDCD4 and anti-actin antibodies was done as described previously (22).

Colorectal tissue samples. Thirty-four endoscopically resected colorectal polyps and 39 surgically excised colorectal tumors were selected from a list of patients with colorectal lesions who underwent endoscopic or surgical operation in 2006. All tissue samples were banked at the Fujita Health University School of Medicine, Aichi, Japan. For the endoscopically resected samples, the patients were between 35 and 83 y old (mean age, 58.8 ± 12.0 y) and included 23 males and 11 females. For the surgically excised samples, the patients were between 41 and 83 y old (mean age, 65.7 ± 9.4 y) and included 23 males and 16 females. Among the 35 cases of surgically removed colorectal cancer, the clinical tumor stage distribution was stage I in 1 patient, stage II in 16 patients, stage III in 15 patients, and stage IV in 2 patients, according to the International Union Against Cancer classification. This study was approved by the institutional ethical review board for human investigation at Fujita Health University.

Results

Detection of miR-21 expression levels by ISH with LNA-modified oligonucleotide probes. To screen for miR-21–positive and miR-21–negative control cultures for ISH, levels of primary transcript of miR-21 (pri-miR-21) and mature miR-21 were determined (Supplementary Fig. S1A and B). Expression level patterns of pri-miR-21 and mature miR-21 were very similar, suggesting that there were no significant rate-limiting steps in the processing of miR-21 production among these cell lines. Among the nine cell lines tested, we used malignant HeLa and MDA-MB435 cells as positive controls and nonmalignant HEK293 cells as a negative control.

A LNA-modified probe was designed in which every third DNA nucleotide was substituted with a corresponding LNA monomer, which was subsequently used for ISH with LNA-modified oligonucleotide probes (LNA-ISH). With fluorescent microscopic observation, the FITC-labeled probe clearly stained the cytoplasm of HeLa and MDA-MB435 cells, whereas HEK293 cell cytoplasmic staining was much weaker (Fig. 1A). Because mature miRNAs are present in the cytoplasm (33), the probe most likely detected the mature miR-21 signals. To apply this LNA-ISH to clinical FFPE samples, we also attempted to detect miR-21 by combining LNA-ISH with the biotin-free tyramide signal amplification system. Using this method, 3,3′-diaminobenzidine staining of miR-21 was visible in the cytoplasm (*brown*; Fig. 1A).

To confirm the specificity of miR-21 detection and more precisely quantify miR-21 expression levels, we produced two lentiviral vectors carrying a portion of pri-miR-21 (including the entire pre-miR-21) driven by the SV40 promoter (polymerase II–driven pLSP-pre-mir21_short) or the mouse U6 promoter (polymerase III–driven pLSP-mU6-pre-mir21_long; Supplementary Fig. S2). HEK293 cells were transduced with pLSP-pre-mir21_short, pLSP-mU6-pre-mir21_long, and pLSP-shGFP (control), respectively, and stable transductants were selected for further analyses. Expression of miR-21 in these established cell lines was analyzed (Supplementary Fig. S3), and LNA-ISH for miR-21 was done. As shown in Fig. 1B, HEK293 cells transduced with miR-21–expressing vectors exhibited a clear cytoplasmic staining when compared with control cells, and pLSP-mU6-pre-mir21_long–transduced cells showed denser staining than pLSP-pre-mir21_short–transduced cells. From these results, we concluded that our LNA-ISH could detect miR-21 in a semiquantitative manner.

High miR-21 expression levels were observed not only in cancer cells but also in cancer-associated fibroblasts from colorectal FFPE tissues. We first performed the LNA-ISH for miR-21 using the surgically excised advanced colorectal cancer tissues. In the 34 slides examined, precancerous adenomatous lesions were found in five cases: three were separate polyps and two were adenomatous masses adjacent to malignant adenocarcinoma. Including these five lesions, we performed the LNA-ISH for miR-21 on 39 lesions (Supplementary Table S1). The expression of miR-21 in adenocarcinoma was much higher than the expression in normal mucosa (Fig. 2; Table 1). In the surgical samples, however, increased miR-21 expression was barely detectable in precancerous adenomas. Unexpectedly, up-regulation of miR-21 was observed not only in malignant cells but also in the stromal fibroblasts adjacent to the tumor (Fig. 2B; Supplementary Fig. S4A; Supplementary Table S1). Overexpression of miR-21 was never observed in fibroblasts far from the tumor mass (Fig. 2B). When an equivalent LNA probe but in which the miR-21 oligonucleotide sequence has been scrambled was used instead, this control probe showed no significant staining in tumor regions, normal tissue, and the stromal fibroblasts adjacent to the tumor (Supplementary Fig. S5B and D), showing clear contrast to the staining by the miR-21 probe in the sequential FFPE colorectal tissue sections (Supplementary Fig. S5A and C). All these results suggest that nonmalignant stromal fibroblasts adjacent to tumors might induce miR-21 expression due to factors secreted from the nearby tumors.

Up-regulation of miR-21 was frequently observed in precancerous adenomas but never in nontumorigenic polyps. We next analyzed miR-21 expression levels in endoscopically resected colorectal polyps that were <15 mm in diameter. Among the 34 samples examined, 28 cases were tumorigenic and 6 cases were nontumorigenic (Table 2; Supplementary Table S2). The ISH signal intensities of these endoscopically resected adenomas were far stronger than those of the five surgically excised adenomas (Supplementary Table S1; Table 1). Importantly, the RNA preservation of endoscopically resected tissues was much better than that of surgical excised tissues. This difference could be due to a longer time before immersion in formalin for the surgical samples (1-3 hours) compared with that for



Fig. 1. ISH with FITC-labeled LNA-modified probe (LNA-ISH) to detect miR-21 expression levels in formalin-fixed human cell lines. *A*, top, combined images of cytoplasmic miR-21 highlighted with FITC signal (*green*) and nuclear DNA counterstained with 4′,6-diamidino-2-phenylindole (*DAPI*; *blue*). Bottom, FITC in the probes were detected by the biotin-free tyramide signal amplification system. MiR-21 is finally stained with 3,3′-diaminobenzidine (*DAB*; *brown*), whereas the nuclei were counterstained with hematoxylin (*blue*). *B*, LNA-ISH detecting miR-21 of HEK293 cells, which were transduced with miR-21 expression vectors (pLSP-pre-mir21_short and pLSP-mU6-pre-mir21_long). Combined images of cytoplasmic miR-21 detected with FITC signal (*green*) and nuclear DNA counterstained with 4′,6-diamidino-2-phenylindole (*blue*). HEK293 cells transduced with pLSP-shGFP were used as a negative control.

endoscopic ones (1-10 minutes) and also to the the much longer formalin fixation time for surgical tissues (24-96 hours) compared with the fixation time for endoscopic ones (<6 hours).

Expression of miR-21 in nontumorigenic lesions was not elevated above levels detected in normal colorectal mucosa (Fig. 3A). On the contrary, increased miR-21 expression was frequently observed in both precancerous adenomas and adenocarcinomas (Fig. 3B and C). As shown in Table 2 and Fig. 3, miR-21 expression was obviously higher in malignant adenocarcinoma than in precancerous adenoma. From these results, we concluded that elevation of miR-21 expression accompanies colorectal tumor development from precancerous adenoma to advanced carcinoma. We also expect that early detection of miR-21 up-regulation may have potential clinical application as a new biomarker for colorectal tumorigenesis.

MiR-21 and PDCD4 expression show mutually exclusive patterns in the areas around colorectal cancer tissues. It has been reported that PDCD4 is a target of miR-21 mostly by transiently introducing miR-21 RNA or antisense oligonucleotides for miR-21 exogenously (20–23). Recently, we have also shown that PDCD4 protein is up-regulated when cells were transduced with lentivirus vectors expressing newly developed decoy RNAs that specifically inhibit miR-21 function (22). We here tested whether HEK293 cells, which show marginal miR-21 expression (Fig. 1), reduce endogenous PDCD4 expression by stable expression of exogenous miR-21. By comparing PDCD4 protein levels in cells transduced with miR-21 expression lentivirus vector (pLSP-mU6-pre-mir21_long) and those with control vectors (or untransduced cells) by Western blotting, we have observed clear reduction in the steady-state levels of PDCD4 by exogenous miR-21 expression (Fig. 2C).

We next performed ISH for miR-21 and immunostaining of PDCD4 using sequential sections obtained from surgically resected colorectal cancer tissues. As shown in Fig. 4A, expression of PDCD4 was high in normal tissues (*right*) but was nondetectable in colorectal cancer cells. Areas with abundant miR-21 expression wrapped over the areas with low PDCD4 expression. Even when endoscopically resected samples were used, mutually exclusive expression patterns were frequently observed between miR-21 and PDCD4 in both malignant adenocarcinoma (Figs. 4B; Supplementary Fig. S6A) and precancerous adenoma



Fig. 2. *A,* LNA-ISH detection of miR-21 in the colorectal adenocarcinoma (*left*) and normal colorectal mucosa (*right*) on the same slide. Bar, 200 μm. *B,* LNA-ISH detection of miR-21 in colorectal tissue from another patient; colorectal adenocarcinoma (*left*) and normal colorectal mucosa (*right*) on the same slide. *, fibroblasts around the cancer; **, fibroblasts around the normal gland. FFPE colorectal tissues were obtained from surgical operation. Bar, 200 μm. *C,* expression of PDCD4 and actin proteins in HEK293 cells transduced with miR-21 expression lentiviral vectors (pLSP-mU6-pre-mir21_long) or two control viral vectors (pLSP-shCre and pLSP-shU3-12). Total protein samples were isolated 2 wk after the transduction and analyzed by Western blotting. Untreated HEK293 cells (nontransduction) were also used as a control.

(Figs. 4C; Supplementary Fig. S6B). These results support the hypothesis that PDCD4 is an *in vivo* target of miR-21 and further suggest that an early increase in miR-21 expression during colorectal tumorigenesis results in a decrease in PDCD4 expression.

Discussion

MiR-21 expression and cancer development. MiR-21 expression has been reported to be one of the best hit miRNA in many profiling experiments designed to detect up-regulated miRNA in human cancer including colorectal carcinoma (3). Our ISH analysis on the colorectal carcinomas clearly detected high level expression of miR-21 in most of them (Fig. 2; Table 1), and importantly, we further showed that this miR-21 increase can be frequently detected from the adenoma stage in the section of endoscopic mucosal resection (Fig. 3; Table 2). Even in this early stage, we observed that PDCD4, a target of miR-21, was concomitantly reduced in miR-21-up-regulated regions (Fig. 4C). These results indicate the importance of up-regulation of miR-21 and down-regulation of PDCD4 as diagnostic biomarkers of colorectal carcinogenesis.

Recently, extensive analysis on miRNA profiles that are associated with prognosis and therapeutic outcome in colon adenocarcinoma was reported (15). Importantly, more advanced tumors expressed higher levels of miR-21 using either microarray data from the test cohort or the quantitative reverse transcription-PCR data from the validation cohort. By analysis on pooled cohorts, they further showed that high miR-21 expression is associated with a poor prognosis in either stage

Table 1. Summary of miR-21 expression levels in surgically excised colorectal adenocarcinoma (malignant tumor) and colorectal adenoma (benign tumor with cancerous potential)

Histologic features of colorectal tumors	Evaluation of miR-21 expression					
	5	4	3	2	1	Total
Adenocarcinoma (malignant tumor)	6	10	8	6	4	34
Adenoma (benign tumor with cancerous potential)	0	0	0	1	4	5

NOTE: Evaluations of the miR-21 expression based on the LNA-ISH staining compared with normal colorectal mucosa on the same slides. Values assigned to the staining (from 1 to 5) were decided as follows: 5, most tumor cells (>80%) show much stronger staining than normal epithelial cells; 4, most tumor cells (>80%) show stronger staining than normal epithelial cells; 3, a part of tumor cells (~20-80%) show stronger staining than normal epithelial cells; 2, some tumor cells (more than 20%) show slightly stronger staining than normal epithelial cells; 1, almost all tumor cells show same staining intensity as normal epithelial cells.

Table 2. Summary of the association between high level expression of miR-21 expression and the histologic features of endoscopically resected colorectal polyps

Histologic features of colorectal polyps		Up-regulation of miR-21			Total
		++	+	−	
Tumorigenic polyp	Noninvasive carcinoma	7	0	1	8
	Adenoma (high or low grade)	8	2	10	20
Nontumorigenic polyp	Hyperplastic	0	0	3	3
	Juvenile	0	0	1	1
	Peutz-Jegher's (hamartomatous)	0	0	2	2

NOTE: Pathohistologic diagnoses were judged by the Vienna classification of gastrointestinal epithelial neoplasia. Evaluations of the intensity of miR-21 staining by LNA-ISH were decided as follows: ++, cells in the polyp show much stronger staining compared with normal epithelial cells on the same slide; +, cells in the polyp show stronger staining compared with normal epithelial cells on the same slide; −, cells in the polyp show the same staining intensity as normal epithelial cells on the same slide.